News | Prostate Cancer | December 14, 2016

Cancer Targeted Technology Commences Phase I Clinical Trial of Prostate Cancer Imaging Agent

Trial will evaluate safety and tolerability of PET agent that binds to PSMA with enhanced uptake and internalization

December 14, 2016 — Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that target pivotal enzyme targets on cancer, announced a Phase I clinical trial has commenced in men with high-risk metastatic prostate cancer. In late August, the U.S. Food and Drug Administration cleared CTT’s first Investigational New Drug Application (IND) for a positron emission tomography (PET) imaging agent, CTT1057, labeled with a two-hour half life radiolabel, fluorine-18, and targeting prostate-specific membrane antigen (PSMA).

PSMA is over-expressed on prostate cancer and this expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s phosphoramidate-based agents bind irreversibly to PSMA and unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells, leading to increased accumulation of the drug and radiolabel within the tumor. The first patient in this trial was imaged in early November and the study is supported by a $2M Small Business Innovation Research (SBIR) grant.

In the trial, CTT1057 will either be used alone or with CTT’s companion radiotherapeutic drug, CTT1403, that targets metastatic prostate cancer, according to CTT CEO and SBIR principal investigator Beatrice Langston-Webster. CTT1403 is currently undergoing IND-enabling studies.”

Automated radiolabeling of the drug and the clinical trials are being conducted at the University of California, San Francisco (UCSF). The principal investigator for the clinical trial is Rahul Aggarwal, M.D. The radiolabeling is directed by UCSF collaborator Henry VanBrocklin, Ph.D., director of the Radiopharmaceutical Research Program, who worked with CTT on the initial development of CTT1057, along with Cliff Berkman, Ph.D., professor of chemistry at Washington State University, who first discovered and synthesized the drug.

VanBrocklin commented, “We are excited to initiate the clinical phase of development of this new imaging agent and look forward to the results of these key studies.”

This CTT-sponsored Phase I trial is entitled “A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA).” The primary objective of this trial is to evaluate the safety and tolerability of CTT1057. An additional endpoint includes the assessment of sensitivity and specificity of CTT1057 PET imaging on a lesion-by-lesion basis as compared with standard imaging in metastatic prostate cancer. Twenty patients will be enrolled in parallel in two cohorts: Cohort A will enroll patients with prostate cancer prior to radical prostatectomy (N = 5) and Cohort B will enroll patients with evidence of metastatic castration-resistant prostate cancer (N = 15). The study is currently enrolling and is expected to conclude in mid 2017.

For more information: www.cancertargetedtechnology.com

Related Content

Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...